Company News-宜明昂科英文

2026-01-09

ImmuneOnco to Attend 44th Annual J.P. Morgan Healthcare Conference and Present Corporate Overview at Biotech Showcase™

Shanghai, China, January 9, 2026 – ImmuneOnco Biopharmaceuticals (Shanghai) Inc. ("ImmuneOnco", HKEX stock code: 01541.HK) announced that a three-person delegation from the company will attend the 44t

2026-01-07

ImmuneOnco Announces IND Acceptance for IMM0306 (Amouravfop Alfa) Monotherapy in Primary Membranous Nephropathy, Advancing Comprehensive Autoimmune Pipeline

NMPA has officially accepted the IND for IMM0306 monotherapy in Primary Membranous Nephropathy (PMN).

2026-01-06

ImmuneOnco Regains Global Rights to IMM2510/AXN-2510 and IMM27M/AXN-27M Following Axion Bio's Discontinuation

SHANGHAI, January 6, 2026 -- ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKEX: 1541.HK) ("ImmuneOnco") today announced that Axion Bio, Inc. (“Axion”), a wholly-owned subsidiary of Instil Bio, Inc.,

2026-01-05

ImmuneOnco R&D Vice President Mr. Li Song Selected for Shanghai's 2025 "Oriental Talent Program"

Recently, the list of selected candidates for the 2025 Shanghai "Oriental Talent Program" (Top Tier) was officially announced. Mr. Li Song, Vice President of Research and Development at ImmuneOnco Bio

2025-12-15

ImmuneOnco Successfully Holds Interim Investigator Meeting in Beijing for Phase Ib/II Clinical Study of Amulirafusp Alfa (IMM0306) Injection in Active Systemic Lupus Erythematosus

ImmuneOnco successfully convened the interim investigator meeting for the "Phase Ib/II Clinical Study of Amulirafusp Alfa (IMM0306) Injection in Active Systemic Lupus Erythematosus (SLE)" in Beijing.